Nanothea S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2015-11-16
Share capital
306,985.00 PLN
Activity description

Nanothea is a company that develops innovative radiopharmaceuticals for the diagnosis and treatment of cancer. They focus on creating precise methods using radioisotopes combined with nanoparticles and targeting conjugates to improve the effectiveness of radiotherapy while minimizing side effects. Their products are designed to ensure non-toxic, FDA-approved materials for safe therapeutic delivery directly to tumors.

Registered address
ul. Rakowiecka 36, 02-532 Warszawa, Poland
Phone
Electronic delivery address
AE:PL-67544-38678-IFWGA-25

Financials

Revenue history (in k)

Financial insights

  • Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
  • The statement flags a going concern risk. Zarząd wskazał znaczącą niepewność co do kontynuacji działalności, wynikającą m.in. z wysokiego ryzyka projektów badawczo-rozwojowych, braku przychodów ze sprzedaży projektów oraz konieczności ciągłego pozyskiwania finansowania.

From the notes

Profit allocationLoss to be covered
Revenue structureProdukty
Shareholders

Filing timeliness

1 of 6 financial statements was filed late (for 2023, 21 days late). All were audited by a statutory auditor.

  • 202514/07/2026
  • 202414/07/2025
  • 202305/08/2024
  • 202206/07/2023
  • 202130/06/2022
  • 202001/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 92%
Top 97%
City · Warszawa53,435 / 56,857
Top 94%
Voivodeship · Mazowieckie73,019 / 77,058
Top 95%
Country · Poland285,112 / 297,566
Top 96%

Results vs industry

Revenue
This companyUSD 115.78MedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -35.22kMedianUSD -293.45AverageUSD 307.82k
Operating costs
This companyUSD 35.27kMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 17.65kMedianUSD 281.58kAverageUSD 8.35m

Offer

  • Radiopharmaceuticals
  • Nanoparticles for cancer diagnostics
  • Conjugates for cancer diagnostics
  • Cancer diagnostic methods
  • Cancer radiotherapy methods

Website technology

Online shop
  • WooCommerce
Website
  • WordPress
Analytics and marketing
  • Google Analytics

Authorized Representatives

Tomasz Adam Ciach age 61 – Management Board Member
Przemysław Daniel Mazurek age 50 – President of the Management Board
Zbigniew Jerzy Posłajko age 56 – Attorney-in-fact (sole)
Piotr Paweł Mierzejewski age 62 – Management Board Member

Manner of representation

In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.

Supervisory board

Robert Artur Dziubłowski age 63 – Supervisory Board Member
Stefan Marcin Bogusławski age 67 – Supervisory Board Member
Jerzy Krzysztof Garlicki age 61 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2016-01-11.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Apr 5, 2017Commercial Companies Code notice
Apr 19, 2016Commercial Companies Code notice

Public aid

6 public aid cases recorded, with a total value of $1,695,336.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282
Aid for research and development projects: industrial research
$299.3K
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$6,814

European Funds

ProjectEU co-financing
Biopolymer nanoparticles as carriers of radioactive isotopes for the early diagnosis of cancer
$1.3M
Development of biopolymer nanoparticles for precise diagnosis and targeted therapy of prostate cancer using radioisotopes
$293.6K

Competitors

Name
Möbius Lab sp. z o.o.
Bioinfobank S.A.
Resolvi sp. z o.o.
Fungotech sp. z o.o.

Change history

DateEvent
2025-09-23Switch to PKD 2025
2024-12-24Share capital increase
2023-09-07Share capital increase
2023-06-12Share capital increase
2022-05-26Share capital increase

FAQ

Last updated: 2026-07-17